Researchers who used PET found that among individuals with early-stage favorable Hodgkin lymphoma and negative scans, those who underwent a combined-modality treatment with ABVD chemotherapy and involved-field radiotherapy had 93.4% five-year progression-free survival, compared with 86.1% among those who received chemotherapy alone. The study, published in the Journal of Clinical Oncology, also found that among those who received CMT, those with positive PET scans had worse five-year PFS than those with negative scans, prompting researchers to suggest more aggressive treatment for those with positive scans after chemotherapy.
PET study evaluates treatments in early Hodgkin lymphoma
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.